The DOI matches its Crossref record; 18 of the 18 references it cites were found in a registry or an index.
A Phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases
Open accessAbstract
BACKGROUND: Osteoprotegerin (OPG) is a decoy receptor for OPG ligand (OPGL), or receptor activator of NF-kappaB ligand (RANKL). RANKL/RANK interaction is important in terminal differentiation and activation of osteoclasts. In binding to RANKL, OPG blocks differentiation and activation of osteoclasts. AMGN-0007 is a recombinant OPG construct developed as a potential therapeutic agent in the treatment of bone disease. METHODS: A randomized, double-blind, double-dummy, active-controlled, single-dose, dose escalation study was conducted to determine the safety and effect on bone resorption of AMGN-0007 in patients with multiple myeloma (n = 28) or breast carcinoma (n = 26) with radiologically confirmed lytic bone lesions. Patients were randomized (3:1 ratio) to receive a single dose of either AMGN-0007 (subcutaneously [SC]) or pamidronate (90 mg intravenously) and were followed for 56 days. Medications or other diseases affecting bone metabolism and chemotherapy within 28 days of dosing were exclusion criteria. Biologic activity of AMGN-0007 was assessed by measurement of the surrogate marker of bone resorption, urinary N-telopeptide of collagen (NTX). RESULTS: AMGN-0007 caused a rapid, sustained, dose-dependent decrease in NTX/creatinine levels, which was at least comparable to the profile observed with pamidronate. Four serious adverse events were reported, three in breast carcinoma patients: a fracture in the left femur (pamidronate, considered unrelated), extreme fatigue (0.3 mg/kg AMGN-0007, considered unrelated), and congestive heart failure (1.0 mg/kg AMGN-0007, considered by the investigator to be probably related to doxorubicin and radiation therapy); one event occurred in a multiple myeloma patient: Herpes zoster (pamidronate, considered unrelated). Two multiple myeloma patients (1.0 mg/kg AMGN-0007) had albumin-adjusted serum calcium levels of 1.9 mmol/L on Day 8 but without clinical symptoms. CONCLUSIONS: A single SC dose of AMGN-0007 suppressed bone resorption as indicated by a rapid, sustained, and profound decrease of urinary NTX/creatinine in multiple myeloma and breast carcinoma patients. Changes were comparable to those with pamidronate. AMGN-0007 was well tolerated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“A dose-dependent reduction in uNTX occurred within 1 d of dosing with OPG-Fc, and uNTX reached a nadir of approximately Ϫ60 and Ϫ84% in the MM and breast cancer strata, respectively, at the higher doses (1.0 and 3.0 mg/kg).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [23]
In the citing paper
“Suppression of bone resorption was maintained throughout the duration of the study (56 d).”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [23]
In the citing paper
“The pharmacodynamic profile of OPG-Fc was generally similar to that observed with the open-label active control, pamidronate.”
From Receptor Activator of Nuclear Factor κB Ligand and Osteoprotegerin Regulation of Bone Remodeling in Health and Disease (2008) · cites this paper as [23]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation.
Lacey, D. L., Timms, E., Tan, H.-L., Kelley, M. J., Dunstan, C. R., Burgess, T., Elliott, R., Colombero, A., Elliott, G., Scully, S., et al. (1998) · Cell · doi:10.1016/s0092-8674(00)81569-x · Cited by 5,439
Self-citationOsteoprotegerin: a novel secreted protein involved in the regulation of bone density.
Simonet, W. S., Lacey, D. L., Dunstan, C. R., Kelley, M., Chang, M.-S., Lüthy, R., Nguyen, H. Q., Wooden, S., Bennett, L., Boone, T., et al. (1997) · Cell · doi:10.1016/s0092-8674(00)80209-3 · Cited by 5,130
Self-citationYasuda, H., Shima, N., Nakagawa, N., Yamaguchi, K., Kinosaki, M., Mochizuki, S.-I., Tomoyasu, A., Yano, K., Goto, M., Murakami, A., et al. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.7.3597 · Cited by 4,224
Efficacy of Pamidronate in Reducing Skeletal Events in Patients with Advanced Multiple Myeloma
Berenson, J. R., Lichtenstein, A. K., Porter, L. L., Dimopoulos, M. A., Bordoni, R., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199602223340802 · Cited by 1,075
Self-citationHortobágyi, G. N., Theriault, R. L., Porter, L. L., Blayney, D. W., Lipton, A., Sinoff, C., Wheeler, H. T., Simeone, J. F., Seaman, J. J., Knight, R., et al. (1996) · New England Journal of Medicine · doi:10.1056/nejm199612123352401 · Cited by 1,024
Self-citationIsolation of a novel cytokine from human fibroblasts that specifically inhibits osteoclastogenesis.
Tsuda, E., Goto, M., Mochizuki, S.-I., Yano, K., Kobayashi, F., Morinaga, T., & Higashio, K. (1997) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.1997.6603 · Cited by 787
Berenson, J. R., Lichtenstein, A. K., Porter, L., Dimopoulos, M. A., Bordoni, R. E., George, S., Lipton, A., Keller, A. M., Ballester, O., Kovacs, M. J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.593 · Cited by 645
Self-citationHortobágyi, G. N., Theriault, R. L., Lipton, A., Porter, L., Blayney, D. W., Sinoff, C., Wheeler, H. T., Simeone, J. F., Seaman, J. J., Knight, R., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.6.2038 · Cited by 630
Self-citationTheriault, R. L., Lipton, A., Hortobágyi, G. N., Leff, R., Glück, S., Stewart, J. F., Costello, S., Kennedy, I., Simeone, J. F., Seaman, J. J., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.3.846 · Cited by 603
Self-citationHonoré, P., Luger, N. M., Sabino, M. A. C., Schwei, M. J., Rogers, S. D., Mach, D. B., O'keefe, P. F., Ramnaraine, M. L. R., Clohisy, D. R., & Mantyh, P. W. (2000) · Nature Medicine · doi:10.1038/74999 · Cited by 497
Flagged first, then by citations
Research works printed but not linked: 2
- Caparelli, 2000, Cancer Res., 60, 783
- Morony, 2001, Cancer Res., 61, 4432
Cited by
Sorted by citations
Items 301–384 of 384
Genetically Engineered Animals
Bolon, B. N. (2007) · Elsevier eBooks · doi:10.1016/b0-08-045044-x/00081-x · Cited by 2
Mundy, G. R., Edwards, C. M., Edwards, J., Lynch, C. C., Sterling, J. A. R., & Zhuang, J. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-373884-4.00005-7 · Cited by 2
Assessment of Therapeutic Response
Freedman, O. C., Clemons, M. J., Vassiliou, V., Kardamakis, D. M., Simmons, C. E., Trinkaus, M., & Chow, E. (2009) · Cancer metastasis · doi:10.1007/978-1-4020-9819-2_17 · Cited by 2
Payne, K. A., Shaw, N. M., Erickson, C. B., Yarger, P., Yu, Y., Baldini, T. H., Kleck, C. J., Patel, V. V., & Burger, E. L. (2022) · Spine · doi:10.1097/brs.0000000000004412 · Cited by 2
Derbel, O., & Blay, J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-416721-6.00037-6 · Cited by 2
How Basic Science Discoveries Have Shaped the Treatment of Bone and Mineral Disorders
Langdahl, B. L., & Ralston, S. H. (2017) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.3316 · Cited by 2
TNF-family member Receptor Activator of NF-κB (RANK) and RANK-Ligand (RANKL) in bone remodelling
Quax, W. J., van Assen, A. H. G., & Wang, Y. Z. (2018) · IOP Conference Series Earth and Environmental Science · doi:10.1088/1755-1315/185/1/012001 · Cited by 2
Future Directions for Zoledronic Acid and New Agents for the Treatment of Bone Metastases
Hei, Y.-J. (2004) · European Urology Supplements · doi:10.1016/j.eursup.2004.08.013 · Cited by 2
Zhou, S., Fang, X., Xin, H., Li, W., Qiu, H., & Guan, S. (2013) · PLoS ONE · doi:10.1371/annotation/a4dbf2d2-f1f0-4a71-b856-7a54f7914666 · Cited by 2
The Pathophysiologic Role of the Bone Marrow Environment and its Niches in Multiple Myeloma
Podar, K., & Anderson, K. C. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374145-5.00326-0 · Cited by 1
Osteoclast Activation in Multiple Myeloma
Vallet, S., & Raje, N. S. (2010) · Humana Press eBooks · doi:10.1007/978-1-60761-554-5_10 · Cited by 1
Potential Therapeutic Targets for Bone Metastasis
Singh, S., & Singh, G. (2004) · Cancer metastasis · doi:10.1007/978-1-4020-2036-0_10 · Cited by 1
Denosumab in the treatment of bone metastases
Woodward, E., & Brown, J. (2012) · Clinical Investigation · doi:10.4155/cli.12.38 · Cited by 1
Blair, J., Modzelewski, J. R. K., Perryman, L., Russell, P. J., Seibel, M. J., & Dunstan, C. R. (2009) · doi:10.29685/jcm.200902.0003 · Cited by 1
Self-citationBone-Targeted Therapy for Prostate Cancer
Gandhok, N. K., & Sartor, O. A. (2004) · Humana Press eBooks · doi:10.1007/978-1-59259-776-5_33 · Cited by 1
Klinische Relevanz von Biomarkern bei der Skelettmetastasierung von Malignomen
Beke, D., Kudlacek, S., & Meran, J. G. (2007) · Wiener Medizinische Wochenschrift · doi:10.1007/s10354-007-0422-x · Cited by 1
Bone metabolism and the development of denosumab: a narrative review
Niu, X.-H., & Xu, H. (2021) · Translational Breast Cancer Research · doi:10.21037/tbcr-20-69 · Cited by 1
Molecular Mechanisms of Castrate Resistant Prostate Cancer
Lamoureux, F., Zoubeidi, A., & Gleave, M. E. (2012) · Springer eBooks · doi:10.1007/978-1-4471-2864-9_4 · Cited by 1
Niches Within the Multiple Myeloma Bone Marrow Microenvironment
Podar, K., Ghobrial, I. M., Hideshima, T., Chauhan, D., & Anderson, K. C. (2007) · Translational medicine series · doi:10.3109/9781420045116.004 · Cited by 1
Insight into the molecular mechanism of action of anticancer drugs
Sengupta, M., Guha, A., Bhowmik, R., Kazmi, I. A., Hosawi, S. B. I., Al-Abbasi, F. A., & Kaleem, M. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-99855-0.00021-x · Cited by 1
Role of Denosumab in Patients with Intermediate Spinal Instability Neoplastic Score (SINS)
Lee, J., Chang, B., Kim, H., Kim, S. T., Jang, S., & Chang, S. Y. (2025) · Cancers · doi:10.3390/cancers17091539 · Cited by 1
RANK and RANKL of Bones, T Cells, and the Mammary Glands
Sigl, V., & Penninger, J. M. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-800571-2.00008-6 · Cited by 1
Influence of the Bone Microenvironment on Breast Cancer Metastasis to Bone
Eckhardt, B. L., Pouliot, N., & Anderson, R. L. (2005) · Springer eBooks · doi:10.1007/1-4020-3414-8_8 · Cited by 1
Breast cancer secreted factors alter the bone microenvironment
Siclari, V. A., Guise, T. A., & Chirgwin, J. M. (2007) · Cancer metastasis · doi:10.1007/978-1-4020-5867-7_12 · Cited by 1
Reyes, M. E. (2014) · Digital Commons-TMC (Texas Medical Center) · Cited by 1
Body, J. J. (2006) · Annales d Endocrinologie · doi:10.1016/s0003-4266(06)72576-8 · Cited by 1
Self-citationOPG, RANK and RANKL in Bone Metastasis and Cancer-Associated Osteolysis
Kostenuik, P. J. (2004) · Cancer metastasis · doi:10.1007/978-1-4020-2036-0_11 · Cited by 1
Kim, D.-H., & Shin, C. S. (2006) · Journal of Korean Endocrine Society · doi:10.3803/jkes.2006.21.3.192 · Cited by 1
Prise en charge des douleurs de métastases osseuses
Caillet, J. B. (2008) · Revue du Rhumatisme · doi:10.1016/j.rhum.2008.01.004 · Cited by 1
Pathophysiology and Management of Bone Metastases in Lung Cancer
Terpos, E., & Syrigos, K. N. (2006) · Springer eBooks · doi:10.1007/3-540-31040-1_48 · Cited by 1
Skeletal Complications of Malignancy: Central Role for the Osteoclast
Clines, G. A., Chirgwin, J. M., & Guise, T. A. (2005) · Springer eBooks · doi:10.1007/1-84628-016-8_9 · Cited by 1
Ramon, A. L., & Malvy, C. (2009) · Springer eBooks · doi:10.1007/978-1-4419-0507-9_16 · Cited by 1
Morton, A. R., & Lipton, A. (2008) · Elsevier eBooks · doi:10.1016/b978-0-443-06694-8.50052-x · Cited by 1
Self-citationObesity- and age-dependent genetic regulation of the plasma proteome in children and adolescentsPreprint
Thielemann, R., Stinson, S. E., Huang, Y., Holm, L. A., Gräf, J. F., Rohde, P. D., Møller, P. L., Poggi, A. I., Anderson, L. V., Fonvig, C. E., et al. (2025) · medRxiv · doi:10.1101/2025.03.18.25324169 · Cited by 1
RANK ligand et métastases osseuses
Beuzeboc, P. (2008) · Springer eBooks · doi:10.1007/978-2-287-36008-4_9
Bolon, B. N., Shalhoub, V., Kostenuik, P. J., Zack, D. J., & Feige, U. (2004) · Birkhäuser Basel eBooks · doi:10.1007/978-3-0348-7883-8_10
Bedeutung von RANK-Ligand und Osteoprotegerin für den Knochenstoffwechsel
Hofbauer, L. C., & Schoppet, M. (2006) · Springer eBooks · doi:10.1007/3-540-28782-5_21
Ashley, D. T. (2010) · Dublin City University Open Access Institutional Repository (Dublin City University)
Benassi, M. S. (2013) · Springer eBooks · doi:10.1007/978-3-319-01748-8_21
Horizontes en el tratamiento farmacológico de la osteoporosis
Arboleya, L. R. (2004) · Revista española de reumatología: Órgano Oficial de la Sociedad Española de Reumatología
Ciblage thérapeutique des tumeurs osseuses primitives par transfert de gène
Lamoureux, F. (2008) · OpenGrey (Institut de l'Information Scientifique et Technique)
Kendler, D. L. (2010) · Orthopedic Research and Reviews · doi:10.2147/orr.s6124
Maung, K., Tyagi, P., & Jain, V. K. (2003) · Supportive Cancer Therapy · doi:10.1016/s1543-2912(13)60073-9
Isolated Humeral Bone Metastasis in Breast Cancer Patient
Madej, B., Bednarek, A., & Janikowska, K. (2009) · Polish Journal of Surgery · doi:10.2478/v10035-009-0086-x
Tuyls, S., Geurs, F., & Deprest, Y. (2013) · Journal of Analytical Oncology · doi:10.6000/1927-7229.2013.02.02.1
Self-citationFouque-Aubert, A., & Chapurlat, R. D. (2007) · Revue du Rhumatisme · doi:10.1016/j.rhum.2007.05.018
Novel Bone-Targeting Agents in Multiple Myeloma
Vallet, S., & Raje, N. S. (2009) · Clinical Lymphoma & Myeloma · doi:10.1016/s1557-9190(11)70829-0
Review Tumor metastasis to bone
Virk, M. S., & Lieberman, J. R. (2007)
Bone Disease in Multiple Myeloma: Pathophysiology and Management
Memorial, K., & Misericordaie, M. (2014)
Rola RANK/RANKL i OPG w szpiczaku plazmocytowym* The role of RANK/RANKL and OPG in multiple myeloma
Kandefer‐Szerszeń, M. (2006)
Topical injection of osteoprotegerin prevents alveolar bone loss in rat experimental periodontitis
Wada-Mihara, C., Tokunaga, K., Seto, H., Sakamoto, E., Hiroshima, Y., Kido, J., & Nagata, T. (2012) · 日本歯周病学会会誌 · doi:10.2329/perio.54.167
Role of Adrenomedullin in Breast Cancer Bone Metastasis and Chemoresistance
Siclari, V. A. (2007) · Defense Technical Information Center (DTIC) · doi:10.21236/ada470977
Les inhibiteurs de RANKL : quel avenir ?
Roux, S. (2005) · Revue du Rhumatisme · doi:10.1016/j.rhum.2005.06.008
Economides, A. N., & Stahl, N. (2013) · Wiley eBooks · doi:10.1002/9781118354599.ch9
Mechanisms and Management of Bone Cancer Pain
Sabino, M. C., & Clohisy, D. R. (2010) · Elsevier eBooks · doi:10.1016/b978-0-12-374895-9.00026-8
Myeloma bone disease – pathogenesis of bone destruction and therapeutic strategies
Chantry, A., & Rabin, N. K. (2013) · Cambridge University Press eBooks · doi:10.1017/cbo9780511862465.008
Bone Preservation Strategies for Men on Androgen Deprivation Therapy
Peyton, C. C., & Balaji, K. C. (2016) · Springer eBooks · doi:10.1007/978-3-319-31341-2_14
Niches Within the Multiple Myeloma Bone Marrow Microenvironment
Podar, K., Ghobrial, I. M., Hideshima, T., Chauhan, D., & Anderson, K. C. (2007) · CRC Press eBooks · doi:10.3109/9781420045116-7
Novel Therapeutic Targets in Multiple Myeloma
Tonon, G. (2007) · CRC Press eBooks · doi:10.3109/9781420045116-8
Grogan, T. M., Gelbspan, D., & Rimsza, L. M. (2004) · CRC Press eBooks · doi:10.1201/b13347-12
Gladd, D. A. (2015)
Биохимические маркеры метастазирования в кости
Russian, N. N. B. (2015)
Padagas, J., Colloton, M., Shalhoub, V., Kostenuik, P. J., Morony, S., Munyakazi, L., Guo, M., Gianneschi, D., Shatzen, E. M., Geng, Z., et al. (2006)
Self-citationParaneoplastic Syndromes: Elements of Interest for the Urologist
Alberti, C., Piovano, M., Zitella, A., & Tizzani, A. (2006) · Urologia Journal · doi:10.1177/039156030607300202
Pathogenesis of Inflammation-Induced Bone Loss
Humphrey, M. B., & Nakamura, M. C. (2006) · Elsevier eBooks · doi:10.1016/b978-0-323-03437-1.50032-4
Therapies of bone metastases in castration-resistant prostate cancer
Lamoureux, F. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00066-9
Maurizi, A., & Rucci, N. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-821666-8.00051-7
Therapie der tumorinduzierten Hyperkalzämie und der tumorinduzierten Osteolyse
M.Flasshove, & Hense, J. (2007) · Springer eBooks · doi:10.1007/978-3-540-28978-4_72
Tanaka, S. (2018) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.733118165.793545404
Morton, A. R., & Lipton, A. (2014) · Elsevier eBooks · doi:10.1016/b978-1-4557-2865-7.00037-0
Self-citationNovel Therapeutic Targets in Multiple Myeloma
Tonon, G. (2007) · Translational medicine series · doi:10.3109/9781420045116.005
Translational Pharmacology in The Development of RANKL Inhibitors
Boyce, B. F., & Yao, Z. (2019) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.62262-6
Benassi, M. S. (2019) · Springer eBooks · doi:10.1007/978-3-030-29676-6_23
Nouvelles approches thérapeutiques des ostéosarcomes.
Wittrant, Y. (2005)
Rôle du système IGF-1/insuline dans le Myélome Multiple
Sprynski, A. C. (2009) · HAL
Modélisation par éléments finis des effets des médicaments sur la résistance de l’os
Boughattas, M. H. (2017) · theses.fr (ABES) · doi:10.70675/09e4577cz66c7z4387zad11z70a4fe10661c
Research Progress of RANK-RANKL Signaling Pathway in Osteoporosis
江, 雨. (2026) · Traditional Chinese Medicine · doi:10.12677/tcm.2026.154228
BindingDB (2021) · UC San Diego · doi:10.7270/q21r6tz8
Metadata
- Authors
- Body, J.-J., Greipp, P., Coleman, R. E., Facon, T., Geurs, F., Fermand, J.-P., Harousseau, J.-L., Lipton, A., Mariette, X., Williams, C. D., Nakanishi, A., Holloway, D., Martin, S. W., Dunstan, C. R., & Bekker, P. J.
- Affiliations
- Institut Jules Bordet (BE)
- Mayo Clinic (US)
- Weston Park Cancer Centre (GB)
- Centre Hospitalier Universitaire de Lille (FR)
- Hôpital Saint-Louis (FR)
- Penn State Milton S. Hershey Medical Center (US)
- The Christie Hospital (GB)
- Amgen (United States) (US)
- Corresponding author
- Bekker, Pirow J.
- ORCID
- Venue
- Cancer
- Publisher
- Wiley
- Published
- 2003-01-23
- Volume
- 97
- Issue
- S3
- Pages
- 887-892
- ISSN
- 0008-543X (ISSN-L)
- 1097-0142
- OpenAlex
- W1986310612
- Cited by
- 383
- References
- 18
- Citations by year
- 2026: 1 · 2025: 2 · 2024: 2 · 2023: 1 · 2022: 7 · 2021: 6 · 2020: 7 · 2019: 9 · 2018: 8 · 2017: 14 · 2016: 7 · 2015: 12 · 2014: 17 · 2013: 19 · 2012: 17
- FWCI
- 17.79
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Cancer (publishedVersion)
- PubMed (publishedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Bone Metabolism and Diseases
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Keywords
- osteoprotegerin, RANKL, RANK, multiple myeloma, breast cancer, bone metastasis, osteolytic lesions, bone resorption, pamidronate, osteoclasts, drug safety, dose escalation, hypercalcemia, congestive heart failure, herpes zoster, phase I
- MeSH terms
- Pamidronate, Antineoplastic Agents, Bone Neoplasms, Bone Resorption, Breast Neoplasms, Diphosphonates, Dose-Response Relationship, Drug, Double-Blind Method, Female, Glycoproteins, Humans, Male, Middle Aged, Multiple Myeloma, Treatment Outcome, Receptors, Tumor Necrosis Factor, Receptors, Cytoplasmic and Nuclear, Osteoprotegerin
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
